Study to Evaluate SHR6390 Combined With Pyrotinib in Patients With HER2 Positive Gastric Cancer
Status:
Unknown status
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to assess the safety and tolerability of SHR6390 combined with
pyrotinib in the patients with Her-2 positive advanced gastric cancer.